Patient Access Programs

Sign in

Register

Sign in

Register

PATIENT ACCESS PROGRAMS

Therapeutic Area

Gastroenterology

Haematology

Neuroscience

Oncology

Rare Diseases

Vaccines

Disease state

Attention deficit hyperactivity disorder (ADHD)

Binge eating disorder (BED)

Crohn’s disease (CD)

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Chronic myelogenous leukemia (CML)

Cutaneous T cell lymphoma (CTCL)

Fabry disease

Gaucher disease

Guillain barre syndrome

Hereditary angioedema (HAE)

Haemophilia

Hodgkins Lymphoma

Idiopathic thrombocytopenia purpura (ITP)

Kawasaki disease

Leukemia

Multifocal motor neuropathy (MMN)

Non-small cell lung cancer (NSCLC)

Primary immunodeficiency disease (PID)

Post transplant cytomegalovirus (CMV)

Pouchitis

Peripheral T cell lymphoma (PTCL)

Short bowel syndrome

Secondary Immunodeficiency disease (SID)

Ulcerative colitis (UC)

Product

ADCETRIS (brentuximab vedotin)

ADVATE (octocog alfa)

ADYNOVATE (rurioctocog alfa pegol)

ALUNBRIG (brigatinib)

CUVITRU (normal immunoglobulin subcutaneous [human] 20%)

ENTYVIO (vedolizumab)

FEIBA NF (factor VIII inhibitor)

ICLUSIG (ponatinib hydrochloride)

INTUNIV (guanfacine hydrochloride)

LIVTENCITY (maribavir)

MEZAVANT (mesalazine)

REPLAGAL (agalsidase alfa ghu)

REVESTIVE (teduglutide)

TAKHZYRO (lanadelumab)

VPRIV (velaglucerase alfa ghu)

VYVANSE (lisdexamfetamine dimesilate)

Search

Sort

Sort by: A-Z

ENTYVIO access

Register to request access to free of charge, TGA approved but non-reimbursed ENTYVIO (vedolizumab) IV doses for Crohn’s disease Week 10 or Q4W dosing for Crohn’s disease or ulcerative colitis.

Access ENTYVIO access

Learn more

You are now leaving the TakedaPro website

This link opens a website that is not operated by Takeda. We are not responsible for the content or availability of linked websites.

Cancel

Continue

Privacy Notice Terms of Use Contact Us Report Adverse Event

Find us on